

HR 6062

To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes.

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 3, 2020

Current Status: Sponsor introductory remarks on measure. (CR H1476)

Latest Action: Sponsor introductory remarks on measure. (CR H1476) (Mar 4, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/6062>

Sponsor

Name: Rep. Schneider, Bradley Scott [D-IL-10]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Hice, Jody B. [R-GA-10]	R · GA		Mar 3, 2020
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Mar 3, 2020
Rep. Pascrell, Bill, Jr. [D-NJ-9]	D · NJ		Mar 12, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Mar 3, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 3, 2020)

This bill expands existing requirements relating to supply shortages of life-saving drugs to also apply to life-saving medical devices.

Generally, a manufacturer must (1) notify the Food and Drug Administration (FDA) of supply interruptions in certain circumstances, (2) provide for the expedited review of a new device that may mitigate the shortage, and (3) allow the FDA to authorize the importation of the device for emergency medical care.

Actions Timeline

- **Mar 4, 2020:** Sponsor introductory remarks on measure. (CR H1476)
- **Mar 3, 2020:** Introduced in House
- **Mar 3, 2020:** Referred to the House Committee on Energy and Commerce.